IDEMIA
1.10.2020 11:59:07 CEST | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, today announces its GREENPAY launch, an eco-friendly global offer for financial institutions, in line with its CSR* and sustainability strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005547/en/
Environmental concerns underpin IDEMIA’s business practices. Through GREENPAY, IDEMIA commits to move away from today’s “take-make-waste” attitude to redesign our habits. IDEMIA is proud to develop solutions generating less plastic and paper waste, reducing land and water pollution while also minimizing its carbon footprint.
GREENPAY is IDEMIA’s commitment to continuously improve each part of the payment card value chain, seeking to:
- Minimize the environmental impact of its processes and services
- Develop innovative, eco-friendly products, services and solutions
- Help customers achieve their environmental goals with IDEMIA’s product offering.
GREENPAY encompasses eco-friendly card body solutions, advanced card related services like eco-designed packaging, on-demand printing of PEFC/FSC certified card carrier, digital alert and e-documents among other services that enable financial institutions to deploy their sustainability transformation.
Over the last few months, IDEMIA’s customers around the world, including Latin America, the US, Europe and Asia, have adopted GREENPAY. For example:
- The RHB 1 Visa WWF Debit Card-i is a recycled PVC payment card which will be available to all new and existing RHB customers in Malaysia from July 2020. The cards contain state-of-the-art technology for seamless payments, have passed all durability tests and are ISO-certified and EMV compliant.
- IDEMIA’s trusted solutions were chosen to accompany BBVA ’s2 customers in the environmental transition journey. This partnership will progressively allow the bank to deliver cards made of “eco friendly” materials to customers in all countries where it has a presence by the end of 2021.
- IDEMIA also offers Treezor 3 , a low-natural-resource-consuming card which does not compromise on security or end-user convenience. The collaboration between IDEMIA and Treezor - French banking-as-a-service market leader - has culminated in the launch of the first ever eco-friendly card by a FinTech in France.
- IDEMIA was also awarded the “Environmental Claim Validation Summary” certification by its recycled PVC supplier “UL Environment Inc.”
Furthermore all GREENPAY products & services – through IDEMIA’s certified partner – financially contribute to key environmental projects around the world in line with the Sustainable Development Goals set up by the United Nations.
IDEMIA’s Executive VP Financial Institutions Amanda Gourbault said: “We at IDEMIA take sustainable development very seriously and believe the financial community is perfectly placed to promote green initiatives and build a better tomorrow. This is GREENPAY’s primary objective, combining all our expertise in technologies which further CSR goals.”
*CSR: Corporate Social Responsibility
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
1
See PR - https://www.idemia.com/press-release/idemia-partners-rhb-bank-launch-first-recycled-debit-card-asia-pacific-2020-06-15
2
See PR - https://www.idemia.com/press-release/idemia-and-bbva-partner-launch-spains-first-payment-card-made-recycled-pvc-2020-06-05
3
See PR - https://www.idemia.com/press-release/idemia-and-treezor-launch-first-eco-friendly-payment-card-onlyone-french-fintech-firm-2020-06-26
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005547/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom